rood blauwe elepsis logo Belegger.nl

Royal Bank Of Scotland Terug naar discussie overzicht

RBS week 46

1 Post
| Omlaag ↓
  1. forum rang 6 benbelegger 12 november 2013 14:29
    Gisteren omhoog, vandaag weer omlaag en dat allemaal vanwege verdeelde adviezen. De toekomst ziet er niet erg rooskleurig uit, zo te zien is rek er uit (voorlopig ).....

    Uit The Guardian:

    Royal Bank of Scotland slips after downbeat broker notes
    Nomura repeats reduce recommendation on bank while Goldman cuts its rating

    Royal Bank of Scotland is among the fallers after analysts at Nomura repeated their reduce recommendation, albeit edging up their price target, and Goldman cut its rating.

    Nomura said investors needed to be patient to see a recovery at RBS - which has set up an internal good and bad bank - and there was potential for disappointment. Analyst Chintan Joshi said:

    RBS's future value is driven by its core profitability. We extend our estimates to 2018, and expect group return on tangible equity to improve from around 6.5%-7% in 2015 to around 12.5% in 2018. Valuations based on 2018 estimates, when discounted to today, offer modest upside. However, a lot can change on such horizons, and valuations are very sensitive to assumptions. We do not see investors willing to look forward five years, and on a three-year outlook we still see material downside from current levels.

    Looking through to 2016, we see core earnings per share excluding [US subsidiary] Citizens Financial Group at 34.2p, which puts RBS on a valuation of around 340p. We also expect dividends and excess capital per share of 12.4p and 31p, respectively. If we discount this to today, we see RBS's fair value at 285p. Litigation charges in excess of £6bn by 2018, Citizens' sale below 1.1 times price to book value, restructuring charges not yet announced, and changes to macro sentiment create downside risk. We retain our reduce rating and prefer Barclays, which trades on similar valuations with better return on equity levels.

    With all that, Nomura has lifted its price target from 270p to 285p.

    At the same time, Goldman Sachs has moved from buy to neutral. In the market RBS has lost 7.2p to 332.6p.

    These new recommendations come just a day after analysts at Jefferies raised their price target on RBS from 390p to 441p, so it is safe to say there is a wide range of views on the bank in the City.
1 Post
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.145
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.356
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.911
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.877
Aedifica 3 927
Aegon 3.258 323.149
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.070
Ahold 3.538 74.353
Air France - KLM 1.025 35.306
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.056
Alfen 16 25.409
Allfunds Group 4 1.521
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.147
AMG 972 134.603
AMS 3 73
Amsterdam Commodities 305 6.748
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.090
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.808
Arcelor Mittal 2.035 321.048
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.362
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.671
ASML 1.766 111.167
ASR Nederland 21 4.518
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.234
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449